Scientific Reports (Nov 2022)

A stable, engineered TL1A ligand co-stimulates T cells via specific binding to DR3

  • Adam Zwolak,
  • Szeman Ruby Chan,
  • Paul Harvilla,
  • Sally Mahady,
  • Anthony A. Armstrong,
  • Leopoldo Luistro,
  • Ninkka Tamot,
  • Douglas Yamada,
  • Mehabaw Derebe,
  • Steven Pomerantz,
  • Mark Chiu,
  • Rajkumar Ganesan,
  • Partha Chowdhury

DOI
https://doi.org/10.1038/s41598-022-24984-y
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 12

Abstract

Read online

Abstract TL1A (TNFSF15) is a TNF superfamily ligand which can bind the TNFRSF member death receptor 3 (DR3) on T cells and the soluble decoy receptor DcR3. Engagement of DR3 on CD4+ or CD8+ effector T cells by TL1A induces downstream signaling, leading to proliferation and an increase in secretion of inflammatory cytokines. We designed a stable recombinant TL1A molecule that (1) displays high monodispersity and stability, (2) displays the ability to activate T cells in vitro and in vivo, and (3) lacks binding to DcR3 while retaining functional activity via DR3. Together these results suggest the TL1A ligand can be amenable to therapeutic development on its own or paired with a tumor-targeting moiety.